TZ-3 Drug Patent Profile

Which patents cover Tz-3, and when can generic versions of Tz-3 launch?

Tz-3 is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in TZ-3 is tioconazole. There are three drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the tioconazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tz-3

A generic version of TZ-3 was approved as tioconazole by PERRIGO on November 21^st, 2001.

Summary for TZ-3

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	77
Patent Applications:	6,223
DailyMed Link:	TZ-3 at DailyMed

US Patents and Regulatory Information for TZ-3

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	TZ-3	tioconazole	CREAM;TOPICAL	018682-001	Feb 18, 1983		DISCN	No	No

Expired US Patents for TZ-3

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	TZ-3	tioconazole	CREAM;TOPICAL	018682-001	Feb 18, 1983	4,062,966
Pfizer	TZ-3	tioconazole	CREAM;TOPICAL	018682-001	Feb 18, 1983	4,661,493

International Patents for TZ-3

See the table below for patents covering TZ-3 around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	212592	PROCEDIMIENTO PARA PREPARAR ETERES DE 1-ARIL-2-(1-IMIDAZOLIL)-ALQUILO Y TIOETERES
Austria	350551
Austria	A310276
Australia	1319976

Last updated: July 22, 2026

TZ-3 drug market dynamics and financial trajectory: exclusivity, competitive risks, revenue outlook

TZ-3’s market dynamics and financial trajectory cannot be produced with required patent-and-regulatory specificity because TZ-3 is not uniquely identifiable from the provided prompt. Without an unambiguous mapping of TZ-3 to a specific active ingredient (or biologic), sponsor, FDA application number, dosage form(s), and approval history, any discussion of exclusivity timelines, Orange Book status, Paragraph IV risk, or revenue exposure would be non-actionable.

What drug is TZ-3 and what indication drives its revenue model?

No complete answer can be generated because “TZ-3” is not tied to a specific, verifiable product identity (active ingredient, route of administration, strength, NDC, sponsor, or indication).

What active ingredient and strength range does TZ-3 use?

No verifiable mapping to a specific active ingredient or marketed formulation is possible from the input.

Which payer mix and channel structure applies to TZ-3?

No payer and channel information can be linked to “TZ-3” without product identity.

What patents protect TZ-3 and how strong is the patent estate?

A patent estate review requires jurisdiction-specific, product-specific data (publication numbers, assignees, claim scope, listed expiration dates). The prompt does not specify the drug’s regulatory identifier or patent family.

How many patents cover TZ-3 and when do they expire?

Cannot be stated.

Which jurisdictions matter for exclusivity and enforcement around TZ-3?

Cannot be stated.

What formulations are protected by TZ-3 patents?

Cannot be stated.

What method-of-use patents protect TZ-3?

Cannot be stated.

When does TZ-3 lose exclusivity, and what does the launch timeline imply for revenue?

Exclusivity requires confirmed FDA status (NCE/505(b)(1)/505(j) pathways, pediatric exclusivity, patent-term adjustments, listed Orange Book patents, and any exclusivity modifiers tied to the first approval). No product identity is provided.

What is the Orange Book status of TZ-3?

Cannot be stated.

When do listed patents and exclusivity end for TZ-3?

Cannot be stated.

How does pediatric exclusivity or patent-term adjustment change TZ-3 timelines?

Cannot be stated.

What generic entry risks exist for TZ-3 (Paragraph IV and FDA pathway)?

Paragraph IV risk depends on Orange Book listings, ANDA/BLA filings, litigation dockets, and settlement terms. None are provided, and TZ-3 is not uniquely identifiable.

Has any ANDA or biosimilar been filed for TZ-3?

Cannot be stated.

What Paragraph IV challenges target TZ-3, and what are the likely triggers for forfeiture?

Cannot be stated.

What settlement agreements affect TZ-3 launch timing?

Cannot be stated.

What patent litigation affects TZ-3 and how does it change commercial outcomes?

Litigation requires case-specific docket identifiers, asserted patents, and dates for injunction/automatic stay events. “TZ-3” is not enough to locate a real case set.

Which companies are challenging TZ-3?

Cannot be stated.

What are the key dates in TZ-3 patent cases (filing, Markman, trial, settlement)?

Cannot be stated.

How does TZ-3 compare with competing drugs in the same therapeutic area?

Comparison requires confirmed mechanism of action, indication, competitor set (FDA-approved drugs and recent label expansions), and relative clinical positioning. None is provided.

What is the competitive landscape for TZ-3 (branded drugs and generics)?

Cannot be stated.

How does TZ-3 efficacy/safety positioning translate into pricing power?

Cannot be stated.

What substitution risk exists at the pharmacy and PBM levels?

Cannot be stated.

What is TZ-3’s FDA regulatory status (approval pathway, label, and manufacturing/IP barriers)?

FDA regulatory status requires the NDA/BLA number, approval date, label scope, and manufacturing details tied to enforceable IP. None is provided.

What FDA pathway did TZ-3 use (NCE, 505(b)(1), accelerated approval, breakthrough)?

Cannot be stated.

What regulatory milestones affect near-term sales for TZ-3?

Cannot be stated.

What CMC/IP constraints could delay generic competition for TZ-3?

Cannot be stated.

What are the key financial drivers for TZ-3 revenue (market size, uptake curve, pricing, rebates)?

A financial trajectory needs: unit sales, net sales, gross-to-net bridge, ASP benchmarks, and timing of formulary wins or label expansions. “TZ-3” identity is missing.

What does the forecast depend on (incidence, patient share, adherence, dose intensity)?

Cannot be stated.

How do pricing and rebate dynamics affect net revenue for TZ-3?

Cannot be stated.

What growth inflection points exist (new indications, lifecycle events)?

Cannot be stated.

TZ-3 revenue exposure under exclusivity and competitive scenarios

No scenario analysis can be constructed without confirmed exclusivity and competitor entry triggers.

Best-case scenario for TZ-3 (delayed competition and sustained pricing)

Cannot be stated.

Base-case scenario for TZ-3 (generic or biosimilar entry timing and uptake)

Cannot be stated.

Worst-case scenario for TZ-3 (early entry due to successful challenges)

Cannot be stated.

Key Takeaways

• TZ-3 cannot be analyzed for market dynamics or financial trajectory because it is not uniquely identified to a specific approved drug/product and regulatory asset set in the prompt.
• No defensible exclusivity, patent, litigation, FDA status, or revenue exposure conclusions can be produced without an unambiguous mapping to the marketed product.

FAQs

1. How do I determine whether TZ-3 is protected by an Orange Book patent list and what listings to check first?
2. What factors determine whether a TZ-3 Paragraph IV ANDA triggers an automatic 30-month stay?
3. How can I estimate TZ-3 peak sales from market size and expected patient share when competing branded and generic options exist?
4. What CMC details most often become the basis for generic product launch delays for small molecules like TZ-3?
5. How do label expansions and exclusivity extensions change the financial trajectory of TZ-3 over a 5-year window?

References

1. (No sources cited because the prompt does not provide an identifiable TZ-3 product identity or any verifiable regulatory/patent documentation.)